Based on public messages from Alan and also when I spoke to him 1:1 at a conference in Sydney in November Alan has always said that they will not give a patient an extra dose just because the trial design says 4 doses if the patient is showing nearly full response in 1, 2 or 3 doses. Similarly they will not give patients a higher dose if they are responding at a lower dose level. This is how clinicians will treat their patients in the real world. So I guess we just have to wait for announcements to know how they went with the trials and which would be patient response based instead of a blanket regimen.
This is IMHO only and I could be wrong. DYOR.
Based on public messages from Alan and also when I spoke to him...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.39 |
Change
0.300(14.4%) |
Mkt cap ! $768.3M | |||
| Open | High | Low | Value | Volume |
| $2.09 | $2.40 | $2.07 | $8.519M | 3.760M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | $2.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.39 | 4380 | 2 |
View Market Depth
| Last trade - 16.21pm 26/06/2025 (20 minute delay) ? |
| CU6 (ASX) Chart |